BioCentury | Jul 20, 2020
Deals

Putting cash to work, BeiGene taps Assembly’s HBV program for first non-oncology deal

A week after adding billions of dollars to its already-deep cash reserves, BeiGene has expanded its pipeline beyond oncology through a deal with Assembly that gives it territorial rights to three clinical HBV programs. Assembly...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BioCentury | Jul 13, 2018
Financial News

Assembly raises $144M follow-on

Assembly Biosciences Inc. (NASDAQ:ASMB) raised $144 million late on July 11 through the sale of 4 million shares at $36 in a follow-on underwritten by Jefferies, Leerink, William Blair, Mizuho Securities, Baird and National Securities...
BioCentury | Jul 12, 2018
Financial News

Assembly raises $144M follow-on

Assembly Biosciences Inc. (NASDAQ:ASMB) raised $144 million late Wednesday through the sale of 4 million shares at $36 in a follow-on underwritten by Jefferies, Leerink, William Blair, Mizuho Securities, Baird and National Securities Corp. The...
BioCentury | Apr 13, 2018
Clinical News

Assembly reports Phase Ib data for HBV candidate

Assembly Biosciences Inc. (NASDAQ:ASMB) reported data from the Phase Ib ABI-H0731-101b trial in treatment-naïve patients with chronic HBV infection showing that ABI-H0731 was generally well tolerated with no serious adverse events or dose-limiting toxicities (DLTs)...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 10, 2017
Financial News

Assembly raises $60.2M in folllow-on

On Nov. 2, Assembly Biosciences Inc. (NASDAQ:ASMB) raised $60.2 million through the sale of 2.2 million shares at $27.25 in a follow-on underwritten by Jefferies and William Blair. The price is a 5% discount to...
BioCentury | Nov 2, 2017
Financial News

Intellia, Assembly price follow-ons

Intellia Therapeutics Inc. (NASDAQ:NTLA) and Assembly Biosciences Inc. (NASDAQ:ASMB) each priced follow-ons, raising more than $210 million. Intellia raised $150 million late Wednesday through the sale of 6.3 million shares at $24 in a follow-on...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
Items per page:
1 - 10 of 12